Pharmacokinetics, pharmacodynamics and safety of recombinant canine FVIIa in a study dosing one haemophilia A and one haemostatically normal dog

Haemophilia

Volumn 17, Issue 6, 2011, Pages 962-970

  Knudsen, T ^a,b   Kristensen, A T ^a   Nichols, T C ^c   Agerso H ^b   Jensen, A L ^a   Kjalke, M ^b   Ezban, M ^b   Tranholm, M ^b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b NOVO NORDISK A S   (Denmark)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Animal model; Haemophilia A; Pharmacodynamics; Pharmacokinetics; Recombinant canine FVIIa; Thromboelastography

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT CANINE BLOOD CLOTTING FACTOR 7A; UNCLASSIFIED DRUG; BLOOD CLOTTING FACTOR 7A; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

ADVERSE OUTCOME; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GENE OVEREXPRESSION; GENE TRANSFER; HEMOPHILIA A; HEMOSTASIS; MALE; NONHUMAN; PRIORITY JOURNAL; THROMBOELASTOGRAPHY; ANIMAL; BLOOD CLOTTING; DISEASE MODEL; DRUG EFFECT; HALF LIFE TIME; INTRAVENOUS DRUG ADMINISTRATION; METABOLIC CLEARANCE RATE; METABOLISM; PILOT STUDY;

ANIMALS; BLOOD COAGULATION; DISEASE MODELS, ANIMAL; DOGS; FACTOR VIIA; FEMALE; HALF-LIFE; HEMOPHILIA A; HEMOSTASIS; INJECTIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; PILOT PROJECTS; RECOMBINANT PROTEINS; THROMBELASTOGRAPHY;

EID: 84857942177     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2011.02536.x     Document Type: Article

References (43)

1. Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost 2004; 2: 899-909.
2. Rapaport SI, Rao LV. The tissue factor pathway: how it has become a 'prima ballerina'. Thromb Haemost 1995; 74: 7-17.
3. Monroe DM, Hoffman M. What does it take to make the perfect clot? Arterioscler Thromb Vasc Biol 2006; 26: 41-8.
4. Kjalke M, Kjellev S, Rojkjaer R. Preferential localization of recombinant factor VIIa to platelets activated with a combination of thrombin and a glycoprotein VI receptor agonist. J Thromb Haemost 2007; 5: 774-80.
5. Monroe DM, Hoffman M, Oliver JA, Roberts HR. Platelet activity of high-dose factor VIIa is independent of tissue factor. Br J Haematol 1997; 99: 542-7.
6. Hedner U, Kisiel W. Use of human factor VIIa in the treatment of two hemophilia A patients with high-titer inhibitors. J Clin Invest 1983; 71: 1836-41.
7. Brinkhous KM, Hedner U, Garris JB, Diness V, Read MS. Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease. Prroc Natl Acad Sci USA 1989; 86: 1382-6.
8. Withnall E, Giger U. Effects of recombinant human activated factor VII and canine fresh frozen plasma in Beagles with hereditary coagulation factor VII deficiency (abstract). J Vet Int Med 2006; 20: 766.
9. Margaritis P, Roy E, Aljamali MN et al. Successful treatment of canine hemophilia by continuous expression of canine FVIIa. Blood 2009; 113: 3682-9.
10. Nichols TC, Dillow AM, Franck HW et al. Protein replacement therapy and gene transfer in canine models of hemophilia A, hemophilia B, von willebrand disease, and factor VII deficiency. ILAR J 2009; 50: 144-67.
11. Knudsen T, Kristensen AT, Sorensen BB, Olsen OH, Stennicke HR, Petersen LC. Characterization of canine coagulation factor VII and its complex formation with tissue factor: canine-human cross-species compatibility. J Thromb Haemost 2010; 8: 1763-72.
12. Knudsen T, Kjalke M, Tranholm M, Nichols TC, Jensen AL, Kristensen AT. Detection of canine coated platelets and their rhFVIIa binding by flow cytometry. Am J Vet Res; in press.
13. Konkle BA, Ebbesen LS, Erhardtsen E et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost 2007; 5: 1904-13.
14. Gopalakrishnan R, Hedner U, Ghosh S, Nayak R, Allen TC, Pendurthi UR, Rao LV. Bio-distribution of pharmacologically administered rFVIIa. J Thromb Haemost 2010; 8(2): 301-10.
15. LeMay DR, LeMay LG, Kluger MJ, D'Alecy LG. Plasma profiles of IL-6 and TNF with fever-inducing doses of lipopolysaccharide in dogs. Am J Physiol 1990; 259: R126-32.
16. Graham JB, Buckwalter JA, Hartley LJ, Brinkhous KM. Canine Hemophilia: observations on the course, the clotting anomaly, and the effect of blood transfusions. J Exp Med 1949; 90: 97-111.
17. Morrissey JH, Macik BG, Neuenschwander PF, Comp PC. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734-44.
18. Callan MB, Aljamali MN, Margaritis P et al. A novel missense mutation responsible for factor VII deficiency in research Beagle colonies. J Thromb Haemost 2006; 4: 2616-22.
19. Knudsen T, Kjelgaard-Hansen M, Tranholm M et al. Canine specific ELISA for coagulation factor VII. Vet J 2011; Accessed April 11, 2011
20. Wiinberg B, Jensen AL, Rozanski E et al. Tissue factor activated thromboelastography correlates to clinical signs of bleeding in dogs. Vet J 2009; 179: 121-9.
21. Ravanat C, Freund M, Dol F et al. Cross-reactivity of human molecular markers for detection of prethrombotic states in various animal species. Blood Coagul Fibrinolysis 1995; 6: 446-55.
22. Mallett SV, Cox DJ. Thrombelastography. Br J Anaesth 1992; 69: 307-13.
23. Bauer N, Eralp O, Moritz A. Establishment of reference intervals for kaolin-activated thromboelastography in dogs including an assessment of the effects of sex and anticoagulant use. J Vet Diagn Invest 2009; 21: 641-8.
24. Roberts HR, Monroe DM III, Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol 2004; 41(Suppl.1): 101-8.
25. Levi M, Peters M, Buller HR. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: a systematic review. Crit Care Med 2005; 33: 883-90.
26. Lindley CM, Sawyer WT, Macik BG et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther 1994; 55: 638-48.
27. Fridberg MJ, Hedner U, Roberts HR, Erhardtsen E. A study of the pharmacokinetics and safety of recombinant activated factor VII in healthy Caucasian and Japanese subjects. Blood Coagul Fibrinolysis 2005; 16: 259-66.
28. Lawson JH, Butenas S, Ribarik N, Mann KG. Complex-dependent inhibition of factor VIIa by antithrombin III and heparin. J Biol Chem 1993; 268: 767-70.
29. Rao LV, Nordfang O, Hoang AD, Pendurthi UR. Mechanism of antithrombin III inhibition of factor VIIa/tissue factor activity on cell surfaces. Comparison with tissue factor pathway inhibitor/factor Xa-induced inhibition of factor VIIa/tissue factor activity. Blood 1995; 85: 121-9.
30. Johansson H, Lukinius A, Moberg L et al. Tissue factor produced by the endocrine cells of the islets of Langerhans is associated with a negative outcome of clinical islet transplantation. Diabetes 2005; 54: 1755-62.
31. Petersen LC, Elm T, Ezban M et al. Plasma elimination kinetics for factor VII are independent of its activation to factor VIIa and complex formation with plasma inhibitors. Thromb Haemost 2009; 101: 818-26.
32. Petersen LC, Karpf DM, Agerso H et al. Intravascular inhibition of factor VIIa and the analogue NN1731 by antithrombin. Br J Haematol 2011; 152: 99-107.
33. Dodds WJ, Packham MA, Rowsell HC, Mustard JF. Factor VII survival and turnover in dogs. Am J Physiol 1967; 213: 36-42.
34. Berrettini M, Mariani G, Schiavoni M et al. Pharmacokinetic evaluation of recombinant, activated factor VII in patients with inherited factor VII deficiency. Haematologica 2001; 86: 640-5.
35. Villar A, Aronis S, Morfini M et al. Pharmacokinetics of activated recombinant coagulation factor VII (NovoSeven) in children vs. adults with haemophilia A. Haemophilia 2004; 10: 352-9.
36. Erhardtsen E. Pharmacokinetics of recombinant activated factor VII (rFVIIa). Semin Thromb Hemost 2000; 26: 385-91.
37. Young G, Ebbesen LS, Viuff D et al. Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial. Blood Coagul Fibrinolysis 2008; 19: 276-82.
38. Young G, Zhang R, Miller R, Yassin D, Nugent DJ. Comparison of kaolin and tissue factor activated thromboelastography in haemophilia. Haemophilia 2010; 16: 518-24.
39. Friederich PW, Henny CP, Messelink EJ et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003; 361: 201-5.
40. Margaritis P, Arruda VR, Aljamali M, Camire RM, Schlachterman A, High KA. Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII. J Clin Invest 2004; 113: 1025-31.
41. Aljamali MN, Margaritis P, Schlachterman A et al. Long-term expression of murine activated factor VII is safe, but elevated levels cause premature mortality. J Clin Invest 2008; 118: 1825-34.
42. Macik BG, Lindley CM, Lusher J et al. Safety and initial clinical efficacy of three dose levels of recombinant activated factor VII (rFVIIa): results of a phase I study. Blood Coagul Fibrinolysis 1993; 4: 521-7.
43. Sabatino DE, Furlan FC, Toso R et al. Recombinant canine B-domain deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model. Blood 2009; 114: 4562-5.